Skip to main content

A hematology clinical trial - AL6

Comparing the usual treatment for younger patients with intermediate risk acute myeloid leukemia to two new approaches
Disease Site
Hematologic Clinical Trials
Trial Code
AL.6 (MM1YA-CTG01) ǀ NCT05554393
Trial Status
Open to patient enrollment

What is the purpose of this study?

The purpose of this study is to compare the usual treatment for acute myeloid leukemia (AML) with two different combinations of treatment.

This trial is part of a larger platform study called myeloMATCH > Find out more.

Why is this study important?

The new treatments being studied are new combinations being developed for the treatment of AML. The new treatments have been studied in a few people and seem promising, but it is not clear if they can offer better results than standard treatment.

Who can participate in this study?

This trial is for:

  • People with previously untreated AML
  • People aged 18 -59 years at the time of induction therapy

This trial is not for:

  • People receiving any other investigational treatment
  • People with isolated myeloid sarcoma
  • People who are pregnant and/or breastfeeding
What are the risks?
  • If you choose to take part in this study, there is a risk that the study approach may not be as good as the standard treatment. 
  • There is also a risk that you could have side effects from the study drugs. 
  • Some of the most common side effects that the study doctors know about are: decrease in the number of red or white blood cells or platelets, constipation, diarrhea, nausea and vomiting, and tiredness or fever. 
  • You will find details of all side effects in the consent document.
What can I expect?
  • If you choose to take part in this study, you will be randomly placed in one of three groups. 
  • You will receive either the usual treatment, the new drug with the usual treatment, or the new drug with another chemotherapy drug.

How can I find out more or join the study?

Talk to your cancer doctor if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you./p>

Before you join this study, you will be asked to review an Informed Consent document which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your standard medical care.

The AL.6 study is currently enrolling patients at cancer centres in Canada. For a full list of participating cancer centres please visit https://clinicaltrials.gov/study/NCT05554393.

For more information about myeloMATCH >

 

Use this trial information for your conversation with your health care team

Participating centres
  • Arthur J.E. Child Comprehensive Cancer Centre - Calgary, AB, T2N 5G2 - Contact: Dr. Mary Lynn Savoie